26 results on '"Beavers, Craig J."'
Search Results
2. Effective medications can work only in patients who take them: Implications for post‐acute heart failure care.
- Author
-
Cotter, Gad, Davison, Beth A., Adams, Kirkwood F., Ambrosy, Andrew P., Atabaeva, Lina, Beavers, Craig J., Bhatt, Ankeet S., Givertz, Michael M., Grodin, Justin L., Lala, Anuradha, Novosadov, Mikhail, Sokos, George G., Takagi, Koji, Teerlink, John R., and Bhatt, Deepak L.
- Subjects
HEART failure ,PATIENTS' attitudes ,DRUGS ,MEDICAL personnel ,PATIENT compliance ,QUALITY of life ,CLINICAL trials monitoring - Abstract
Acute heart failure (AHF) is a common cause of hospitalization, particularly among older individuals, and has high mortality and readmission rates. Adherence to guideline-directed medical therapy (GDMT) is crucial for improving outcomes in heart failure (HF) patients, as non-adherence can lead to exacerbations and adverse outcomes. However, studies have shown that medication non-adherence rates among HF patients can be as high as 70%. Various factors contribute to non-adherence, including patient circumstances, treatment-related factors, and healthcare system and payer factors. Adherence interventions, such as patient education, medication regimen management, and reminders, have been shown to improve medication adherence and reduce mortality and hospital readmissions in HF patients. Improving adherence to GDMT is essential for improving AHF outcomes, and further research is needed to identify effective approaches to enhance medication adherence. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
3. Defining pharmacist activities in ambulatory heart failure clinics: North American survey and modified Delphi study.
- Author
-
Beauchesne, Arielle B. M., Koshman, Sheri L., Beavers, Craig J., Gorman, Sean K., and Turgeon, Ricky D.
- Subjects
PHARMACISTS ,HEART failure ,CANADIANS ,MEDICAL practice ,LIKERT scale - Abstract
Background: Pharmacists are key members of multidisciplinary heart failure (HF) clinics; however, there is variation in their roles and activities. This study aimed to: (1) define current roles of HF clinic pharmacists and (2) develop a consensus‐based list of key activities for HF clinic pharmacists. Methods: In part 1, we invited Canadian and American HF clinic pharmacists to complete a survey on activities currently performed in the HF clinic. Part 2 consisted of a three‐round modified Delphi study including only Canadian participants to define key activities for ambulatory HF pharmacists among 44 candidates. In each round, participants rated a list of candidate activities based on importance and priority on a 9‐point Likert scale. Consensus was reached for inclusion when ≥75% of participants rated both criteria ≥7, or exclusion when both criteria ≤6. Participants received personal responses alongside aggregate ratings after each round to facilitate attainment of consensus. Results: Eighty‐four pharmacists participated in part 1, and 29 (of 55 invited) participated in part 2 (24 retained for all three rounds). Current pharmacist activities were similar between American and Canadian participants, with an emphasis on patient assessment and clinical activities including modification of HF‐specific pharmacotherapy. The final consensus‐based list included 32 activities, with high priority placed on activities involving optimization of medications for HF and common comorbidities, engaging in shared decision‐making, assessing adherence, reviewing lab tests, and assessing and modifying medications due to pharmacokinetic/pharmacodynamic parameters, which closely mirrored activities in current practice. Conclusion: Current activities of ambulatory HF pharmacists are largely consistent within North America, focusing on patient assessment and HF‐specific pharmacotherapy modification. Our consensus‐based list defined 32 activities integral to the future role of pharmacists in HF clinics, which builds upon activities being currently performed. This provides a framework to standardize and expand the scope of practice for clinical pharmacy services in HF clinics. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Part I: PSAP Live: Updates from 2022 Book 1 (Cardiology).
- Author
-
Beavers, Craig J., Rudd, Kelly M., and Kaluzna, Stephanie Dwyer
- Subjects
HEART failure ,MYOCARDIAL infarction ,CORONARY artery bypass ,PLATELET aggregation inhibitors - Abstract
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Ivabradine and empagliflozin Ivabradine and spironolactone Spironolactone and empagliflozin Empagliflozin only B Part II: Oral anticoagulants in patients with antiphospholipid syndrome. b You are evaluating a patient with a history of arterial thrombus for a potential diagnosis of antiphospholipid syndrome (APS). Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. Catastrophic APS Obstetric APS Primary APS Secondary APS A 38-year-old man with secondary APS presents with recurrent arterial thrombotic event while on adequate warfarin therapy. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
5. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
- Author
-
Beavers, Craig J.
- Abstract
Purpose of Review: Finerenone is a novel, non-steroidal mineralocorticoid receptor antagonist (MRAs) that has been investigated for the management of cardiorenal conditions. This article provides an overview of recent evidence of benefits on cardiovascular (CV) outcomes. Recent Findings: The recently published phase III FIDELIO-DKD and FIGARO-DKD, alone and pooled, in patients with CKD and diabetes demonstrate that finerenone reduces the composite of CV death, non-fatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure (HF) with hospitalization for HF being the primary driver of this composite. Summary: Finerenone is indicated to reduce renal and CV outcomes in patients with CKD and diabetes. Future investigations of this agent include patients with non-diabetic CKD, HF with preserved ejection fraction, and with the use of sodium-glucose transporter type 2 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women.
- Author
-
Patel, Shreya, Kumar, Manish, Beavers, Craig J., Karamat, Saad, and Alenezi, Fawaz
- Abstract
Purpose of Review: The intent of this review is to provide an update in polypharmacy in older adults and women with a focus on common determinants and strategies to mitigate polypharmacy. Recent Findings: Polypharmacy is becoming a critical focus in the management of cardiovascular diseases. It may emerge unintentionally while managing multimorbidity in older adults or in the vulnerable subgroup of patients, such as pregnant and lactating females. Clinicians should utilize several approaches such as deprescribing, sex-specific risk assessment, and encouraging healthy lifestyle to minimize inappropriate and unnecessary use of medications. Summary: A shared decision-making model along with coordination and collaboration among healthcare providers should be utilized in the selection and management of pharmacotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Reply to 'The pharmacist ally in heart failure: Useful when involved'.
- Author
-
Beavers, Craig J., Bhatt, Deepak L., and Gotter, Gad
- Subjects
- *
HEART failure , *PHARMACISTS - Abstract
Pharmacists play a crucial role in the management of heart failure, contributing to patient-specific, facility-specific, and population services. They are key stakeholders in ensuring the optimization of guideline-directed medical therapy (GDMT) for heart failure patients, including medication selection, optimization, and adherence. Studies have shown that involving pharmacists in the care team leads to higher rates of achieving GDMT, resulting in lower mortality and hospitalization rates. However, there are challenges in embedding pharmacists in all clinical settings globally, including training, access, and scope of practice. Health institutions, clinicians, and organizations need to advocate for the inclusion of pharmacists in heart failure care and support their training and development. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
8. Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
- Author
-
Beavers, Craig J. PharmD, FACC, FCCP, BCCP, BCPS, CACP, Effoe, Samuel. Aaron PharmD, and Dobesh, Paul P. PharmD, FCCP, BCPS, BCCP
- Published
- 2022
- Full Text
- View/download PDF
9. Development and application of quality measures of clinical pharmacist services provided in inpatient/acute care settings.
- Author
-
Acquisto, Nicole M., Beavers, Craig J., Bolesta, Scott, Buckley, Mitchell S., Dobbins, Kelsey F., Finch, Christopher K., Hayes, Sarah M., Holdren, Danielle B., Johnson, Steven T., Kane‐Gill, Sandra L., and Lat, Ishaq
- Abstract
As health care transitions to value‐based care, it is more critical than ever to emphasize and quantify the impact on patient outcomes made by inpatient/acute care pharmacists and pharmacist extenders as members of the interprofessional care team. Thus, the American College of Clinical Pharmacy (ACCP) took to task the development of quality measures that were broadly applicable to the diverse inpatient/acute care landscape and important for standardizing practice, measuring impact, contextualizing benefit within the health care landscape, and allowing benchmarking within and between institutions. A framework was established by the writing committee of this paper in order to develop quality measures in a methodical manner. The resulting process led the writing committee to devise 31 foundational quality measures to be used in efforts to champion the pharmacist's role in achieving the quadruple aims in health care. Application and evaluation of quality measure performance as well as limitations and future implications of the measures are addressed to further highlight the evolving role of the inpatient/acute care pharmacist and pharmacist extender. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Optimizing anticoagulation for patients receiving Impella support.
- Author
-
Beavers, Craig J., DiDomenico, Robert J., Dunn, Steven P., Cox, Jenna, To, Long, Weeks, Phillip, Trujillo, Toby C., and Jennings, Douglas L.
- Subjects
- *
HEPARIN , *ARTIFICIAL blood circulation , *ANTICOAGULANTS , *EXTRACORPOREAL membrane oxygenation - Abstract
Anticoagulation of patients treated with the Impella percutaneous mechanical circulatory support (MCS) devices is complex and lacks consistency across centers, potentially increasing the risk of complications. In order to optimize safety and efficacy, an expert committee synthesized all available evidence evaluating anticoagulation for patients receiving Impella support in order to provide consensus recommendations for the management of anticoagulation with these devices. The evidence synthesis led to the creation of 42 recommendations to improve anticoagulation management related to the use of the Impella devices. Recommendations address purge solution management, intravenous anticoagulation, monitoring, evaluation and management of heparin‐induced thrombocytopenia (HIT), and management during combination MCS support. The use of a heparinized, dextrose‐containing purge solution is critical for optimal device function, and a bicarbonate‐based purge solution may be an alternative in certain situations. Likewise, intravenous (ie, systemic) anticoagulation with heparin is often necessary, although evidence supporting the optimal assay and target range for monitoring the level of anticoagulation is generally lacking. Patients treated with an Impella MCS device may develop HIT, which is more difficult to evaluate and treat in this setting. Lastly, the use of Impella with extracorporeal membrane oxygenation or for biventricular support creates additional anticoagulation challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Evaluation of an interactive online information service to improve patient care in the field of anticoagulation and antithrombotic therapy.
- Author
-
Bussey, Henry I. and Beavers, Craig J.
- Subjects
PATIENT care ,BLOOD coagulation ,FIBRINOLYTIC agents - Abstract
Background: The ClotCare Online Information Resource ("ClotCare") was established in 2000 as an interactive patient education service. In 2003, its scope of service was expanded to include clinicians and the general public, and an editorial board was added to facilitate dissemination of new information. By 2008, the site had achieved national and international recognition. Methods: Website use statistics and an online survey were used to assess geographic reach and clinical impact in 2010. Results: The site experienced an annual growth of over 40% (with the use doubling every 2 years). ClotCare answered over 1000 questions per year, web traffic exceeded 500 000 "hits" per month and more than 5000 individuals subscribed to the email list serve. Of the 826 individuals who responded to the survey, 55% subscribed to the email list serve, 58% were health care professionals, 31% were patients, and 11% were "individuals seeking information on blood clots and related issues". United States residents comprised 87% of respondents; the others resided in 20 different countries. Data from completed surveys revealed that 367 of 412 health care professionals (89%) and 259 of 298 patients (87%) could identify a specific change in practice that they had made due to information from ClotCare. Among the 295 "frequent users," 94% to 98% agreed or strongly agreed that ClotCare increased their knowledge, provided valuable information, provided trusted information, provided a valuable service, and is among the top five resources utilized for information on blood clots and related treatments. Conclusions: ClotCare substantially altered the actions of both health care professionals and patients. These outcomes have been achieved through web‐based education and information sharing as well as "on demand" responses to questions. ClotCare is a widely used resource that is highly valued. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Use of Glycoprotein IIb/IIIa Inhibitors in the Modern Era of Acute Coronary Syndrome Management: A Survey of Cardiovascular Clinical Pharmacists.
- Author
-
Beavers, Craig J. and Jennings, Douglas L.
- Subjects
- *
ATTITUDES of medical personnel , *ACUTE coronary syndrome , *MYOCARDIAL infarction , *PHARMACISTS , *GLYCOPROTEINS , *QUESTIONNAIRES , *CHEMICAL inhibitors - Abstract
Evidence for the use of glycoprotein IIb/IIIa inhibitors (GPIs) in the management of acute coronary syndrome (ACS) is from the era of either limited utilization of P2Y12 inhibitors or prior the introduction of more potent P2Y12 inhibitors. This leads to divergent opinions regarding the role of these agents in contemporary practice. This study sought the opinion of cardiovascular clinical pharmacists regarding the role of GPIs in the modern of ACS management. A 13-question survey was created and distributed from June 2018 to July 2018 via the American College of Clinical Pharmacy's Cardiology Practice and Research Network e-mail listserv. The survey consisted of questions regarding the ideal use of GPIs in ACS management, preferred agent selection, and rational for selection. All results were analyzed with descriptive statistics. There were a total 69 responses of 1175 (response rate 5.9%). The majority felt there was still a role for GPI in accordance to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for ST-segment elevation myocardial infarction (65.2%), with eptifibatide being preferred (55.1%). For non-ST-segment myocardial infraction (NSTEMI), only 49.3% felt role of GPI was in line with the ACC/AHA guidelines, but a notable number of respondents felt GPIs were only indicated in NSTEMI patients for bailout or thrombotic complications (18.8%). A majority (56.5%) felt GPIs could be used as an alternative for cangrelor when bridging. The decision to use one agent over another were efficacy data, cost, and pharmacokinetic profile. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Current and future state of clinical pharmacist‐led precision medicine initiatives.
- Author
-
Tillman, Emma M., Beavers, Craig J., Afanasjeva, Janna, Momary, Kathryn M., Strnad, Kyle G., Yerramilli, Aparna, Williams, Anne M., Smith, Brooke A., Florczykowski, Brittany, and Fahmy, Monica
- Subjects
PHARMACISTS ,INDIVIDUALIZED medicine ,PHARMACOGENOMICS - Abstract
This white paper evaluates the current and future state of clinical pharmacist‐led precision medicine initiatives, focusing on an overview of pharmacogenomics (PGx) in three key areas: clinical practice, education, and research. These key facets are described in detail, followed by a review of potential and perceived barriers concerning PGx and recommendations for the clinical pharmacist's role in overcoming these barriers. This paper reviews the current state of clinical pharmacist‐led precision medicine and presents a vision for the future of pharmacy practice in this quickly evolving field. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Osocimab: A Novel Agent in Preventing Venous Thromboembolism.
- Author
-
Beavers, Craig J. and Wayne, Nathaniel B.
- Published
- 2020
- Full Text
- View/download PDF
15. Role of Bempedoic Acid in Dyslipidemia Management.
- Author
-
Kelly, Michael S., Sulaica, Elisabeth M., and Beavers, Craig J.
- Published
- 2020
- Full Text
- View/download PDF
16. Reduced dose thrombolysis with ultrasound-facilitated catheter-directed administration for acute pulmonary embolism reduces length of stay.
- Author
-
Wayne, Nathaniel B., Davis, George A., Macaulay, Tracy E., Beavers, Craig J., Messerli, Adrian W., Dugan, Adam, and Smyth, Susan S.
- Abstract
The optimal dose and duration of tissue plasminogen activator (tPA) administered with ultrasound-facilitated catheter-directed thrombolysis (USCDT) to patients with acute PE remains to be determined. Our institution recently adopted a shorter duration (4 h) of USCDT and lower dosing strategy (tPA 1 mg/h) based on data from the OPTALYSE PE Trial. The purpose was to evaluate the implementation at our institution of shorter duration (4 h) of USCDT and lower dosing strategy (tPA 1 mg/h) as outlined by OPTALYSE PE Trial. This was a retrospective, single-center, observational study included patients from 01/01/2017 to 12/31/2018 in a large, academic medical center. Group 1 represented patients who underwent USCDT prior to 01/18/18. Group 2 represented patients who underwent USCDT after 01/18/18 and received 4 h of USCDT and tPA 1 mg/h/catheter. The primary outcome was intensive care unit (ICU) length of stay (LOS). Secondary outcomes were the proportion of patients experiencing a composite of major adverse events (death, recurrent PE, major bleeding, or stroke), change in right ventricle size/function and pulmonary artery pressures, need for mechanical respiratory or hemodynamic support, hospital LOS and drug cost. A total of 31 patients were included in the study: twenty patients in Group 1 and eleven patients in Group 2. Median ICU LOS was 3.5 days in Group 1 and 1 day in Group 2. Group 2 had reduced MACE, requirement for mechanical respiratory or hemodynamic support, hospital LOS, drug costs and adverse events. Implementation of a shorter duration of USCDT and lower dosing strategy for tPA in patients with acute PE may be one strategy to reduce the total ICU LOS and costs associated with care. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Still sour about lactic acidosis years later: role of metformin in heart failure.
- Author
-
Kuan, William, Beavers, Craig J., and Guglin, Maya E.
- Subjects
HYPOGLYCEMIC agents ,METFORMIN ,TYPE 2 diabetes complications ,BLOOD sugar ,HEART failure ,TYPE 2 diabetes ,SURVIVAL ,WORLD health ,DISEASE incidence ,LACTIC acidosis ,DISEASE complications - Abstract
Metformin remains a widely-used, first-line pharmacotherapy agent for patients with type 2 diabetes mellitus because of its efficacy, mild side effects, and affordability.However, use of this medication has traditionally been shunned by clinicians in patient populations that are considered at risk of lactic acidosis, such as those with heart failure. The underutilization of metformin can largely be attributed to the historical stigma of its biguanide predecessor, phenformin, and its association with lactic acidosis. Despite various studies finding low rates of lactic acidosis and the United States Federal Drug Administration's subsequent removal of heart failure from metformin's contraindication labeling in 2006, this oral hypoglycemic remains underutilized in this patient population. In addition to reports of the safe use of metformin in the heart failure population, a multitude of studies have also additionally suggested a modest reduction in mortality and morbidity. Metformin's role should be strongly reconsidered in the armamentarium of diabetes management in heart failure patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. The National Practice Patterns of Venous Thromboembolism Prophylaxis Post-Cardiothoracic Surgery.
- Author
-
Mathew, Sheena E., Beavers, Craig J., and McNeely, Elizabeth
- Abstract
Background: The rates of venous thromboembolism (VTE) post-cardiothoracic surgery are not well understood. The american college of chest physicians (CHEST) guidelines report weak recommendations for starting VTE prophylaxis post-cardiothoracic surgery. It is suspected that due to the increase in bleed risk, postsurgery initiation of pharmacologic VTE prophylaxis is limited. Objective: The study sought to investigate the use of VTE prevention in US hospitals performing cardiac surgery and the use of mechanical/chemical prophylaxis postoperatively. Methods: This is a multicenter survey distributed to cardiac hospitals in the United States. The survey was distributed through 3 separate listservs. Data were analyzed utilizing descriptive statistics. Results: The majority of the hospitals were academic and/or community and completed coronary artery bypass graft (CABG), valve replacement (mitral/aortic/tricuspid), and aortic repair. It was common for hospitals to start mechanical and pharmacologic prophylaxis post-cardiothoracic surgery on postoperative day (POD) 1 to 2. The anticoagulation most commonly used consisted of unfractionated heparin. Conclusions: The majority of the institutions are initiating therapy POD 1 to 2 with both mechanical and chemical prophylaxis. The full impact of early initiation of VTE prophylaxis is unknown, and more studies are needed to assess the true risks/benefits of these practices. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. Obesity and Antiplatelets-Does One Size Fit All?
- Author
-
Beavers, Craig J., Heron, Paula, Smyth, Susan S., Bain, Jonathan A., and Macaulay, Tracy E.
- Subjects
- *
PLATELET aggregation inhibitors , *OBESITY treatment , *VASCULAR diseases , *PHARMACODYNAMICS , *BODY mass index , *PATIENTS ,TREATMENT of vascular diseases - Abstract
Antiplatelet therapy has become a cornerstone in the management of many vascular diseases. With growing antiplatelet options, attention has focused on their comparative effectiveness in specific patient populations. Perhaps one of the least defined factors influencing efficacy of these agents is body mass and obesity. Evidence from preclinical models established that obesity promotes inflammation that in turn enhances platelet reactivity. Thus, adiposity has the potential to diminish or alter the therapeutic effect of antiplatelet therapy. Pharmacodynamic analyses suggest a potential need for dose adjustments of antiplatelet therapy in obese patients. Yet, obese patients paradoxically have better outcomes after acute coronary syndromes. In this review, we identify a critical need for clinical studies with outcome data to enable the development of recommendations for optimal antiplatelet regimens in obese individuals. Until such data exists, healthcare providers should be aware of the potential impact of obesity on the efficacy of anti-platelet therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. BICARBONATE-BASED PURGE SOLUTION DURING IMPELLA SUPPORT: A GROWING ALTERNATIVE.
- Author
-
Beavers, Craig J., Dunn, Steven P., DiDomenico, Robert J., Moretz, Jeremy, and Jennings, Douglas L.
- Published
- 2022
- Full Text
- View/download PDF
21. Distinguishing Anemia and Iron Deficiency of Heart Failure: Signal for Severity of Disease or Unmet Therapeutic Need?
- Author
-
Beavers, Craig J., Alburikan, Khalid A., Rodgers, Jo E., Dunn, Steven P., and Reed, Brent N.
- Subjects
- *
HEART failure , *IRON deficiency , *ANEMIA , *BLOOD transfusion , *INFLAMMATION - Abstract
Despite advances in the management of heart failure ( HF), quality of life and other outcomes remain suboptimal for many patients. Anemia and iron deficiency are comorbidities associated with adverse outcomes, although their pathophysiology in the setting of HF is not entirely understood. Anemia and iron deficiency may exist independently and may be a consequence of the systemic inflammatory state characterized by chronic HF. However, it is unclear whether serum hemoglobin concentrations and other hematologic parameters serve as markers for the severity of disease or represent novel therapeutic targets. Research in this area has focused primarily on therapies known to be effective for these conditions in other chronic disease states with similar pathophysiologic features (e.g., end-stage renal disease). Despite its many practical advantages, minimal evidence exists to support the use of oral iron supplementation in this setting. In contrast, intravenous iron has been the subject of several recent investigations, demonstrating improvements in both surrogate and clinical end points, although benefits seem to be the most substantial in patients with concomitant anemia. Erythropoietin-stimulating agents demonstrated early promise in retrospective analyses and small prospective trials, but their benefit was outweighed by a lack of improvement in clinical outcomes and an excess number of thromboembolic events in the largest trial of patients with anemia and HF to date. For acute symptomatic anemia, blood transfusion may be considered, although few trials have included patients with HF, and caution must be exerted in those who are hemodynamically unstable. Based on the currently available evidence, treatment of iron deficiency appears to confer benefit in patients with HF, whereas strategies aimed at improving hemoglobin alone do not. Included is a review of the pathophysiology of these conditions in the setting of HF, clinical trials evaluating pharmacologic therapy, and recommendations for management. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
22. Meta-Analysis Comparing Carvedilol Versus Metoprolol for the Prevention of Postoperative Atrial Fibrillation Following Coronary Artery Bypass Grafting.
- Author
-
DiNicolantonio, James J., Beavers, Craig J., Menezes, Arthur R., Lavie, Carl J., O'Keefe, James H., Meier, Pascal, Vorobcsuk, András, Aradi, Dániel, Komócsi, András, Chatterjee, Saurav, D'Ascenzo, Fabrizio, Gasparini, Mauro, Brugts, Jasper, and Biondi-Zoccai, Giuseppe
- Subjects
- *
METOPROLOL , *ADRENERGIC beta blockers , *CORONARY artery bypass , *ATRIAL fibrillation prevention , *DISEASE incidence , *DRUG efficacy , *META-analysis ,PREVENTION of surgical complications - Abstract
A systematic review and meta-analysis was performed to evaluate the effects of carvedilol versus metoprolol on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting in randomized controlled trials. Ovid MEDLINE, PubMed, CENTRAL, and Excepta Medica (EMBASE) were searched up to March 2013 for suitable randomized controlled trials. Data were pooled using random-effects model for pairwise analyses. A total of 4 trials with 601 patients were included in this analysis. Pairwise analyses showed that compared with metoprolol, carvedilol significantly reduced the incidence of postoperative atrial fibrillation (odds ratio 0.50, 95% confidence interval 0.32 to 0.80). In conclusion, compared with metoprolol, carvedilol significantly reduces the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Key Articles and Guidelines in the Management of Acute Coronary Syndrome and in Percutaneous Coronary Intervention: 2012 Update.
- Author
-
Dobesh, Paul P., Beavers, Craig J., Herring, Holly R., Spinler, Sarah A., Stacy, Zachary A., and Trujillo, Toby C.
- Subjects
- *
ACUTE coronary syndrome , *CARDIOVASCULAR disease treatment , *PATIENT management , *DRUG therapy , *PHARMACOGENOMICS , *CLOPIDOGREL , *CORONARY disease - Abstract
More than 1 million people in the United States experience an acute coronary syndrome ( ACS) every year, and almost 600,000 undergo percutaneous coronary intervention ( PCI) for treatment of cardiovascular disease. There is a large amount of evidence-based literature to guide appropriate management of these patients. There have been a number of advances in the treatment of these patients over the last several years. Due to the large amount of rapidly available literature concerning the care of patients with ACS or undergoing PCI, clinicians can often find it difficult to keep up with the information needed for optimizing care of these patients. Therefore, we provide the second update to the first compiled bibliography of key articles and guidelines relative to patients with ACS published in Pharmacotherapy in 2004. The initial update was published in Pharmacotherapy in 2007 and also included bibliographies concerning management of patients undergoing PCI. A number of guidelines and practice-changing literature have been published since the update in 2007. Specific areas included in this review are updated summaries of clinical practice guidelines and clinical trials of anticoagulants, antiplatelets, platelet aggregation testing, pharmacogenomics testing in patients taking clopidogrel, clopidogrel loading dose comparisons, clopidogrel and proton pump inhibitor drug interactions, the impact of bleeding in ACS, and statins. As with previous versions of this document, we hope that this compilation will serve as a resource for pharmacists, physicians, nurses, residents, and students responsible for the care of patients with coronary heart disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee.
- Author
-
Kumbhani, Dharam J., Cannon, Christopher P., Beavers, Craig J., Bhatt, Deepak L., Cuker, Adam, Gluckman, Ty J., Marine, Joseph E., Mehran, Roxana, Messe, Steven R., Patel, Nimesh S., Peterson, Benjamin E., Rosenfield, Kenneth, Spinler, Sarah A., Thourani, Vinod H., and Writing Committee
- Subjects
- *
INTERNATIONAL normalized ratio , *PERCUTANEOUS coronary intervention , *CEREBRAL embolism & thrombosis , *ATRIAL fibrillation , *THROMBOEMBOLISM , *TRANSIENT ischemic attack , *LEGISLATIVE oversight , *CARDIOVASCULAR diseases , *CARDIOVASCULAR disease treatment , *ATRIAL fibrillation treatment , *CARDIOLOGY , *VEINS , *MEDICAL care , *CARDIOVASCULAR system , *PLATELET aggregation inhibitors , *MEDICAL societies , *DISEASE complications ,THROMBOEMBOLISM prevention - Abstract
This article has been temporarily removed as it was inadvertently posted ahead of an agreed-upon embargo. The article will be reinstated upon embargo expiry. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
- Author
-
Noel, Zachary R. and Beavers, Craig J.
- Subjects
- *
PROPROTEIN convertases , *SUBTILISINS , *ENZYME inhibitors , *LOW density lipoproteins , *DRUG interactions - Abstract
Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events. It is critical for all providers to have a basic understanding of these novel therapies with their introduction and use for treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. The role of the clinical pharmacist in the care of patients with cardiovascular disease.
- Author
-
Dunn, Steven P., Birtcher, Kim K., Beavers, Craig J., Baker, William L., Brouse, Sara D., IIPage, Robert L., Bittner, Vera, Walsh, Mary Norine, and Page, Robert L 2nd
- Abstract
Team-based cardiovascular care, including the use of clinical pharmacists, can efficiently deliver high-quality care. This Joint Council Perspectives paper from the Cardiovascular Team and Prevention Councils of the American College of Cardiology provides background information on the clinical pharmacist's role, training, certification, and potential utilization in a variety of practice models. Selected systematic reviews and meta-analyses, highlighting the benefit of clinical pharmacy services, are summarized. Clinical pharmacists have a substantial effect in a wide variety of roles in inpatient and ambulatory settings, largely through optimization of drug use, avoidance of adverse drug events, and transitional care activities focusing on medication reconciliation and patient education. Expansion of clinical pharmacy services is often impeded by policy, legislation, and compensation barriers. Multidisciplinary organizations, including the American College of Cardiology, should support efforts to overcome these barriers, allowing pharmacists to deliver high-quality patient care to the full extent of their education and training. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.